What's New in MEN1 Diagnosis and Management
Omair -- Shariq, MD, MS
Mayo Clinic
In this session, we will explore recent advancements in the genetic and clinical diagnosis of multiple endocrine neoplasia type 1 (MEN1), highlighting the distinctions between genotype-positive and genotype-negative patients. The session will also discuss the latest modalities and technologies that have emerged for the diagnosis of MEN1-related manifestations, and their implications for early detection and disease management. Therapeutic strategies for MEN1-related primary hyperparathyroidism (PHPT), duodeno-pancreatic neuroendocrine tumors (DP-NETs), and pituitary adenomas will be reviewed, with updates on both surgical and pharmacological treatments. Key topics include challenges in diagnosing and managing Zollinger-Ellison syndrome, the development of reliable biomarkers of behavior for non-functioning pancreatic NETs, and the optimal extent and timing of surgical interventions for MEN1-related PHPT.